Palvella Reports Late-Stage Success for Rare Disease Drug
WAYNE, PA — Palvella Therapeutics (Nasdaq: PVLA) reported new late-stage clinical data showing strong patient response rates for its experimental QTORIN rapamycin treatment in rare vascular malformations, positioning the company …
Palvella Reports Late-Stage Success for Rare Disease Drug Read More